Nootkatone as a multi-target modulator of the PD-L1/PD-1 signaling in pancreatic cancer: network pharmacology,
Karan Goel1, Thakur Gurjeet Singh1, Somdutt Mujwar2
1Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
Abstract:
Pancreatic cancer is a major cause of death and one of the most challenging types of cancer which responds poorly to conventional chemotherapy and has limited therapeutic options. The scenario highlights the urgent need for the development of newer multi-targeting anticancer drugs for pancreatic cancers with higher potency, selectivity and safety profiles. The proposed research was focused on revealing the anticancer potential and mechanistic involvement of naturally occurring sesquiterpenoid nootkatone against pancreatic cancer through an integrative in silico approach. Network pharmacology and systems biology approaches were applied to identify common therapeutic targets for nootkatone that were pathophysiologically associated with the progression of pancreatic cancer. Protein-protein interaction (PPI), Gene Ontology (GO), and KEGG enrichment analyses were executed to validate the target's involvement in the pathophysiology of pancreatic cancer. Molecular docking and dynamics simulations were performed to reveal the binding potential and interactions of the nootkatone with the shortlisted anticancer targets, followed by density functional theory (DFT) analysis, ADMET prediction, and clinical relevance assessment to confirm its electrochemical and physicochemical involvement. A total of 27 overlapping targets were identified with AKT1, MAPK3, IL1β, and COX-2 revealed as the four hub target genes for nootkatone by network pharmacology. Enrichment analyses confirmed the significant involvement of PD-L1/PD-1 immune checkpoint, PI3K-AKT, MAPK, and inflammatory signaling pathways (FDR < 0.05) in the progression of pancreatic cancer. Docking analyses revealed that nootkatone has binding affinity for its targets, especially for MAPK3/ERK1 (- 8.03 kcal/mol) and AKT1 (- 7.35 kcal/mol). MD simulation over 100 ns demonstrated the stable protein-ligand complexes. DFT calculations showed a HOMO-LUMO energy gap of 2.868 eV, indicating moderate chemical reactivity and stability. Nootkatone was found to exert stronger and more stable binding against all four concerned anticancer targets with impressive electrochemical properties. ADMET predictions suggested favourable drug-likeness and Pharmacokinetics. Nootkatone can be a potential multi-targeting agent with anticancer and immunomodulatory properties by modulating the PD-L1/PD-1 immune checkpoint and signalling pathways associated with pancreatic cancer progression. However, these findings are based on in silico analyses and require further validation through in vitro and in vivo experimental studies to develop new plant-based anticancer therapeutics for pancreatic cancer.
Insights
Nootkatone, a natural compound, shows potential as a multi-targeting anticancer agent for pancreatic cancer by interacting with key pathways like PD-L1/PD-1. Further research is needed to validate these promising in silico findings for therapeutic development.
Area of Science:
- Computational drug discovery
- Systems biology
- Natural product chemistry
Background:
- Pancreatic cancer presents significant therapeutic challenges due to poor response to conventional treatments.
- There is a critical need for novel, multi-targeting anticancer drugs with improved efficacy and safety profiles.
- Nootkatone, a naturally occurring sesquiterpenoid, is explored for its potential anticancer properties.
Purpose of the Study:
- To investigate the anticancer potential of nootkatone against pancreatic cancer using an integrated in silico approach.
- To identify and validate therapeutic targets and molecular pathways involved in pancreatic cancer progression modulated by nootkatone.
Main Methods:
- Network pharmacology and systems biology were employed to identify nootkatone's therapeutic targets in pancreatic cancer.
- Protein-protein interaction (PPI), Gene Ontology (GO), and KEGG pathway analyses were performed for target validation.
- Molecular docking, molecular dynamics (MD) simulations, density functional theory (DFT) analysis, and ADMET prediction were utilized.
Main Results:
- Twenty-seven overlapping targets were identified, with AKT1, MAPK3, IL1β, and COX-2 highlighted as key targets.
- Nootkatone demonstrated significant binding affinity for targets like MAPK3/ERK1 (-8.03 kcal/mol) and AKT1 (-7.35 kcal/mol).
- In silico analyses indicated stable protein-ligand complexes, favorable drug-likeness, and potential immunomodulatory effects via the PD-L1/PD-1 checkpoint.
Conclusions:
- Nootkatone exhibits potential as a multi-targeting agent against pancreatic cancer, modulating critical signaling pathways and immune checkpoints.
- The compound possesses favorable physicochemical and pharmacokinetic properties based on computational predictions.
- Further in vitro and in vivo studies are warranted to validate nootkatone's therapeutic efficacy for pancreatic cancer.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:41Non-Canonical Wnt Signaling Pathways
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...